AKT1 and neoplasm: Targeting tumor drivers such as FGFR, IDH1/2, PI3K-AKT-mTOR, MEK/ERK, and YAP/TAZ in combination with metabolic inhibitors offers a promising strategy to overcome resistance to ICIs (162).